Study finds 2013 ACC/AHA guideline led to immediate improvements in optimal statin use for ASCVD patients and enhanced 5-year MACE survival for populations with ASCVD or diabetes in the US.
Transmasculine patients undergoing GAHT may experience adverse lipid profile changes, unlike transfeminine counterparts, which investigators say is cause for closer monitoring.